Identification

Name
Pancuronium
Accession Number
DB01337
Type
Small Molecule
Groups
Approved
Description

A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.

Structure
Thumb
Synonyms
  • Bromure de pancuronium
  • Bromuro de pancuronio
  • Pancuronium
Product Ingredients
IngredientUNIICASInChI Key
Pancuronium bromideU9LY9Y75X215500-66-0NPIJXCQZLFKBMV-YTGGZNJNSA-L
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pancuronium Bromide - Liq IV 1mg/mlLiquid1 mgIntravenousSandoz Canada Incorporated1995-12-31Not applicableCanada
Pancuronium Bromide - Liq IV 2mg/mlLiquid2 mgIntravenousSandoz Canada Incorporated1996-12-31Not applicableCanada
Pancuronium Bromide 1mg/mlSolution1 mgIntravenousHospira, Inc.1996-10-24Not applicableCanada
Pancuronium Bromide 2mg/mlSolution2 mgIntravenousHospira, Inc.1995-12-31Not applicableCanada
Pavulon Inj 1mg/mlLiquid1 mgIntravenousOrganon Canada Ltd Ltee1979-12-311997-08-18Canada
Pavulon Inj 2mg/mlLiquid2 mgIntravenousOrganon Canada Ltd Ltee1973-12-311997-08-18Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pancuronium BromideInjection, solution1 mg/mLIntravenousTeva Parenteral Medicines, Inc.1990-08-012017-02-25Us
Pancuronium BromideInjection, solution2 mg/mLIntravenousTeva Parenteral Medicines, Inc.1990-08-012017-02-25Us
Pancuronium BromideInjection, solution2 mg/mLIntravenousTeva Parenteral Medicines, Inc.1990-08-012017-02-25Us
Pancuronium BromideInjection, solution1 mg/mLIntravenousHospira, Inc.1989-01-19Not applicableUs
International/Other Brands
Mioblock / Pavulon
Categories
UNII
J76UF062FS
CAS number
Not Available
Weight
Average: 572.8619
Monoisotopic: 572.455308418
Chemical Formula
C35H60N2O4
InChI Key
GVEAYVLWDAFXET-XGHATYIMSA-N
InChI
InChI=1S/C35H60N2O4/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36/h26-33H,7-23H2,1-6H3/q+2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-/m0/s1
IUPAC Name
1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-13-(1-methylpiperidin-1-ium-1-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-4-yl]-1-methylpiperidin-1-ium
SMILES

Pharmacology

Indication

Used as a muscle relaxant during anesthesia and surgical procedures.

Structured Indications
Not Available
Pharmacodynamics

Pancuronium is a typical non-depolarising curare-mimetic muscle relaxant. It acts as a competitive acetylcholine antagonist on neuromuscular junctions, displacing acetylcholine (hence competitive) from its post-synaptic nicotinic acetylcholine receptors. It is, unlike suxamethonium, a non-depolarising agent, which means, that it causes no spontaneous depolarisations upon association with the nicotinic receptor in neuromuscular junction, thus producing no muscle fasciculations upon administration. Pancuronium has no hormonal activity. It exerts slight vagolytic activity (i.e. diminishing activity of the vagus nerve) and no ganglioplegic (i.e., blocking ganglions) activity.

Mechanism of action

Nondepolarizing neuromuscular blocking agents inhibit neuromuscular transmission by competing with acetylcholine for the cholinergic receptors of the motor end plate, thereby reducing the response of the end plate to acetylcholine. This type of neuromuscular block is usually antagonized by anticholinesterase agents.

TargetActionsOrganism
ANeuronal acetylcholine receptor subunit alpha-2
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
Absorption
Not Available
Volume of distribution
  • 241 to 280 mL/kg
Protein binding

77 to 91%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

1.5 to 2.7 hours.

Clearance
  • Plasma cl=1.1–1.9 mL/minute/kg
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AcetyldigitoxinPancuronium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinPancuronium may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AclarubicinAclarubicin may increase the respiratory depressant activities of Pancuronium.Investigational
AclidiniumPancuronium may increase the anticholinergic activities of Aclidinium.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Pancuronium is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pancuronium is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Ambenonium.Approved
Ambroxol acefyllinateThe risk or severity of adverse effects can be increased when Ambroxol acefyllinate is combined with Pancuronium.Experimental, Investigational
AmikacinAmikacin may increase the respiratory depressant activities of Pancuronium.Approved, Vet Approved
AminophyllineThe risk or severity of adverse effects can be increased when Aminophylline is combined with Pancuronium.Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pancuronium.Approved
annamycinannamycin may increase the respiratory depressant activities of Pancuronium.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Pancuronium.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational
AtracuriumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Pancuronium.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Pancuronium.Approved, Vet Approved
BekanamycinBekanamycin may increase the respiratory depressant activities of Pancuronium.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Pancuronium.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Pancuronium.Approved
BezitramideThe risk or severity of adverse effects can be increased when Pancuronium is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Pancuronium.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Pancuronium.Experimental
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Pancuronium.Approved, Investigational
Botulinum Toxin Type BPancuronium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BumetanideBumetanide may decrease the neuromuscular blocking activities of Pancuronium.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Pancuronium is combined with Butorphanol.Approved, Illicit, Vet Approved
ButylscopolamineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Scopolamine butylbromide.Approved, Vet Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Pancuronium.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Pancuronium is combined with Carfentanil.Illicit, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Pancuronium.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Chlorphenoxamine.Withdrawn
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Pancuronium.Approved, Investigational, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Pancuronium.Approved
CimetropiumPancuronium may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
ClindamycinClindamycin may increase the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Codeine.Approved, Illicit
ColistimethateColistimethate may increase the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
CoumaphosThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Pancuronium.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pancuronium.Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Pancuronium.Approved, Investigational, Vet Approved
CymarinPancuronium may increase the arrhythmogenic activities of Cymarin.Experimental
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Pancuronium.Approved, Investigational
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Pancuronium.Approved
DecamethoniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Demecarium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Pancuronium.Approved
DeslanosidePancuronium may increase the arrhythmogenic activities of Deslanoside.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pancuronium.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Pancuronium.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dezocine.Approved, Investigational
DibekacinDibekacin may increase the respiratory depressant activities of Pancuronium.Experimental
DichlorvosThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pancuronium.Approved
DigitoxinPancuronium may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinPancuronium may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Pancuronium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Pancuronium.Investigational, Vet Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Pancuronium is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Donepezil.Approved
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Pancuronium.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Pancuronium is combined with DPDPE.Experimental
DronabinolPancuronium may increase the tachycardic activities of Dronabinol.Approved, Illicit
DyphyllineThe risk or severity of adverse effects can be increased when Dyphylline is combined with Pancuronium.Approved
EchothiophateThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Edrophonium.Approved
EluxadolinePancuronium may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Emepronium.Experimental
EpirubicinEpirubicin may increase the respiratory depressant activities of Pancuronium.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Pancuronium.Approved
EtanautineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Pancuronium.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Pancuronium is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Fesoterodine.Approved
FramycetinFramycetin may increase the respiratory depressant activities of Pancuronium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
GalantamineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pancuronium.Approved
GeneticinGeneticin may increase the respiratory depressant activities of Pancuronium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Pancuronium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Pancuronium.Experimental
GitoformatePancuronium may increase the arrhythmogenic activities of Gitoformate.Experimental
Glucagon recombinantThe risk or severity of adverse effects can be increased when Pancuronium is combined with Glucagon recombinant.Approved
GlycopyrroniumPancuronium may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GPX-150GPX-150 may increase the respiratory depressant activities of Pancuronium.Investigational
HeroinThe risk or severity of adverse effects can be increased when Pancuronium is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Pancuronium.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pancuronium.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Hydromorphone.Approved, Illicit
Hygromycin BHygromycin B may increase the respiratory depressant activities of Pancuronium.Vet Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pancuronium.Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Pancuronium.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Pancuronium.Approved
INNO-206INNO-206 may increase the respiratory depressant activities of Pancuronium.Investigational
IpidacrineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pancuronium.Approved
IsepamicinIsepamicin may increase the respiratory depressant activities of Pancuronium.Experimental
IsoflurophateThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Pancuronium.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational, Vet Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Ketobemidone.Approved, Investigational
Lanatoside CPancuronium may increase the arrhythmogenic activities of Lanatoside C.Experimental
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pancuronium is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Pancuronium is combined with Levorphanol.Approved
LincomycinLincomycin may increase the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
LithiumLithium may increase the neuromuscular blocking activities of Pancuronium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Pancuronium is combined with Lofentanil.Illicit
Magnesium HydroxideMagnesium Hydroxide may increase the neuromuscular blocking activities of Pancuronium.Approved
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Pancuronium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Pancuronium.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
MalathionThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Pancuronium is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Pancuronium.Approved
MefloquineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Pancuronium is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pancuronium is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Pancuronium.Approved, Investigational
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Pancuronium.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Pancuronium is combined with Methylscopolamine bromide.Approved
MetildigoxinPancuronium may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetixeneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Pancuronium.Approved
MetrizamideMetrizamide may increase the respiratory depressant activities of Pancuronium.Approved
MianserinMianserin may increase the anticholinergic activities of Pancuronium.Approved, Investigational
MicronomicinMicronomicin may increase the respiratory depressant activities of Pancuronium.Experimental
MinaprineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Minaprine.Approved
MinocyclineMinocycline may increase the neuromuscular blocking activities of Pancuronium.Approved, Investigational
MirabegronThe risk or severity of adverse effects can be increased when Pancuronium is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Morphine.Approved, Investigational
NabilonePancuronium may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Nalbuphine.Approved
NeamineNeamine may increase the respiratory depressant activities of Pancuronium.Experimental
NeomycinNeomycin may increase the respiratory depressant activities of Pancuronium.Approved, Vet Approved
NeostigmineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Normethadone.Approved, Illicit
OleandrinPancuronium may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OpiumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Pancuronium.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Otilonium.Experimental, Investigational
OuabainPancuronium may increase the arrhythmogenic activities of Ouabain.Approved
OxitropiumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Pancuronium.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Pancuronium is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pancuronium.Approved
ParaoxonThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Paraoxon.Experimental
ParomomycinParomomycin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Pancuronium.Approved
PeruvosidePancuronium may increase the arrhythmogenic activities of Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Pancuronium.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Pipecuronium.Approved
PirarubicinPirarubicin may increase the respiratory depressant activities of Pancuronium.Investigational
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Pancuronium.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Pancuronium.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Pancuronium is combined with Piritramide.Investigational
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Pancuronium.Vet Approved
PlazomicinPlazomicin may increase the respiratory depressant activities of Pancuronium.Investigational
PlicamycinPlicamycin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Pancuronium.Approved, Vet Approved
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Pancuronium.Approved
Potassium ChloridePancuronium may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Pancuronium.Approved, Investigational
ProcainamideProcainamide may increase the neuromuscular blocking activities of Pancuronium.Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Pancuronium.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Pancuronium.Approved
PropiverineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Propiverine.Approved, Investigational
ProscillaridinPancuronium may increase the arrhythmogenic activities of Proscillaridin.Experimental
PuromycinPuromycin may increase the respiratory depressant activities of Pancuronium.Experimental
PyridostigmineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Pancuronium.Approved
QuinidineQuinidine may increase the neuromuscular blocking activities of Pancuronium.Approved
QuinineQuinine may increase the neuromuscular blocking activities of Pancuronium.Approved
RamosetronPancuronium may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Pancuronium is combined with Remifentanil.Approved
RibostamycinRibostamycin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational
RivastigmineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Rivastigmine.Approved, Investigational
SabarubicinSabarubicin may increase the respiratory depressant activities of Pancuronium.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pancuronium.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Pancuronium.Approved, Investigational
SisomicinSisomicin may increase the respiratory depressant activities of Pancuronium.Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Pancuronium is combined with Solifenacin.Approved
SP1049CSP1049C may increase the respiratory depressant activities of Pancuronium.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational, Vet Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Pancuronium.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Pancuronium.Approved
SufentanilThe risk or severity of adverse effects can be increased when Pancuronium is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Pancuronium.Approved, Investigational
TacrineThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Pancuronium is combined with Tapentadol.Approved
TheophyllineThe risk or severity of adverse effects can be increased when Theophylline is combined with Pancuronium.Approved
TilidineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Tilidine.Experimental
TiotropiumPancuronium may increase the anticholinergic activities of Tiotropium.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Pancuronium.Approved, Investigational
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Pancuronium.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Pancuronium is combined with Topiramate.Approved
TorasemideTorasemide may decrease the neuromuscular blocking activities of Pancuronium.Approved
TramadolThe risk or severity of adverse effects can be increased when Pancuronium is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Pancuronium.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pancuronium.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Pancuronium.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Pancuronium is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Pancuronium.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Pancuronium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Pancuronium.Approved
UmeclidiniumPancuronium may increase the anticholinergic activities of Umeclidinium.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Pancuronium.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Pancuronium.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Vecuronium.Approved
Zoptarelin doxorubicinZoptarelin doxorubicin may increase the respiratory depressant activities of Pancuronium.Investigational
ZorubicinZorubicin may increase the respiratory depressant activities of Pancuronium.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15430
KEGG Compound
C07551
PubChem Compound
441289
PubChem Substance
46506118
ChemSpider
390052
ChEBI
7907
ChEMBL
CHEMBL185073
Therapeutic Targets Database
DAP000123
PharmGKB
PA450771
IUPHAR
4001
Guide to Pharmacology
GtP Drug Page
Wikipedia
Pancuronium
ATC Codes
M03AC01 — Pancuronium
AHFS Codes
  • 12:20.20 — Neuromuscular Blocking Agents

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous1 mg/mL
Injection, solutionIntravenous2 mg/mL
SolutionIntravenous1 mg
SolutionIntravenous2 mg
LiquidIntravenous1 mg
LiquidIntravenous2 mg
Prices
Unit descriptionCostUnit
Pancuronium 2 mg/ml vial2.59USD ml
Pancuronium 1 mg/ml vial0.13USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)215 °CPhysProp
water solubility5E+005 mg/LMERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility3.08e-06 mg/mLALOGPS
logP1.04ALOGPS
logP-3.3ChemAxon
logS-8.3ALOGPS
pKa (Strongest Basic)-6.7ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area52.6 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity185.22 m3·mol-1ChemAxon
Polarizability69.44 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8913
Blood Brain Barrier+0.878
Caco-2 permeable+0.5457
P-glycoprotein substrateSubstrate0.77
P-glycoprotein inhibitor IInhibitor0.6962
P-glycoprotein inhibitor IIInhibitor0.6508
Renal organic cation transporterNon-inhibitor0.6862
CYP450 2C9 substrateNon-substrate0.8382
CYP450 2D6 substrateNon-substrate0.7638
CYP450 3A4 substrateSubstrate0.742
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9229
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9368
Ames testNon AMES toxic0.7499
CarcinogenicityNon-carcinogens0.9265
BiodegradationNot ready biodegradable0.8557
Rat acute toxicity2.6653 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9021
hERG inhibition (predictor II)Non-inhibitor0.7784
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Androstane steroids / Piperidines / Dicarboxylic acids and derivatives / Tetraalkylammonium salts / Carboxylic acid esters / Azacyclic compounds / Organopnictogen compounds / Organic salts / Organic oxides / Hydrocarbon derivatives
show 3 more
Substituents
Steroid ester / Androstane-skeleton / Dicarboxylic acid or derivatives / Piperidine / Quaternary ammonium salt / Tetraalkylammonium salt / Carboxylic acid ester / Organoheterocyclic compound / Carboxylic acid derivative / Azacycle
show 12 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
acetate ester, steroid ester (CHEBI:7907)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  2. Dilger JP, Vidal AM, Liu M, Mettewie C, Suzuki T, Pham A, Demazumder D: Roles of amino acids and subunits in determining the inhibition of nicotinic acetylcholine receptors by competitive antagonists. Anesthesiology. 2007 Jun;106(6):1186-95. [PubMed:17525594]
  3. Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Milchert M, Spassov A, Meissner K, Nedeljkov V, Lehmann C, Wendt M, Loster BW, Mazurkiewicz-Janik M, Gedrange T, Pavlovic D: Skeletal muscle relaxants inhibit rat tracheal smooth muscle tone in vitro. J Physiol Pharmacol. 2009 Dec;60 Suppl 8:5-11. [PubMed:20400785]
  2. Cembala TM, Forde SC, Appadu BL, Lambert DG: Allosteric interaction of the neuromuscular blockers vecuronium and pancuronium with recombinant human muscarinic M2 receptors. Eur J Pharmacol. 2007 Aug 13;569(1-2):37-40. Epub 2007 May 22. [PubMed:17588565]
  3. Okanlami OA, Fryer AD, Hirshman C: Interaction of nondepolarizing muscle relaxants with M2 and M3 muscarinic receptors in guinea pig lung and heart. Anesthesiology. 1996 Jan;84(1):155-61. [PubMed:8572329]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Milchert M, Spassov A, Meissner K, Nedeljkov V, Lehmann C, Wendt M, Loster BW, Mazurkiewicz-Janik M, Gedrange T, Pavlovic D: Skeletal muscle relaxants inhibit rat tracheal smooth muscle tone in vitro. J Physiol Pharmacol. 2009 Dec;60 Suppl 8:5-11. [PubMed:20400785]
  2. Okanlami OA, Fryer AD, Hirshman C: Interaction of nondepolarizing muscle relaxants with M2 and M3 muscarinic receptors in guinea pig lung and heart. Anesthesiology. 1996 Jan;84(1):155-61. [PubMed:8572329]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Stovner J, Oftedal N, Holmboe J: The inhibition of cholinesterases by pancuronium. Br J Anaesth. 1975 Sep;47(9):949-54. [PubMed:1191483]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257]
  2. Busch AE, Quester S, Ulzheimer JC, Waldegger S, Gorboulev V, Arndt P, Lang F, Koepsell H: Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem. 1996 Dec 20;271(51):32599-604. [PubMed:8955087]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81. [PubMed:9260930]

Drug created on June 30, 2007 12:07 / Updated on December 10, 2017 17:18